Crossmark

Letter to the Editor Regarding “Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo Adjusted Indirect Treatment Comparison”

Crossref DOI link: https://doi.org/10.1007/s13555-025-01622-9

Published Online: 2025-12-29

Published Print: 2026-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chovatiya, Raj

Seminario-Vidal, Lucia https://orcid.org/0000-0002-6004-2451
Gallo, Gaia

Ding, Yuxin

Yang, Chao

Akmaz, Bülent

Solé-Feu, Laia

Rand, Kim
Funding

Funding for this research was provided by:

Eli Lilly and Company
License Information

Text and Data Mining valid from 2025-12-29

Version of Record valid from 2025-12-29
More Information

Article History

Received: 8 October 2025

Accepted: 5 December 2025

First Online: 29 December 2025

Declarations

:

: Raj Chovatiya served as an advisor, consultant, speaker, and/or investigator for AbbVie, Acelyrin, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeutics Inc., Argenx, Astria Therapeutics Inc., Avalere Health, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, CLn Skin Care, Dermavant, Eli Lilly and Company, EMD Serono, Formation Bio, Galderma, Genentech, GSK, Incyte, Johnson & Johnson, Kenvue, LEO Pharma, L’Oréal, Nektar Therapeutics, Novartis, Opsidio, Pfizer Inc., RAPT, Regeneron, Sanofi, Sitryx, Takeda, TRex Bio, and UCB. Lucia Seminario-Vidal, Gaia Gallo, Yuxin Ding, and Chao Yang are employees of, and own stock in, Eli Lilly and Company, which funded this research. Bülent Akmaz and Laia Solé-Feu are employees of Almirall. Kim Rand is an employee of Maths In Health B.V.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Document is current

Any future updates will be listed below